SCNLF (Scancell Holdings) Book Value per Share: $-0.01 (As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
16 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Book Value per Share?

Scancell Holdings SCNLF 16 Book Value per Share is $-0.01 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Scancell Holdings's book value per share for the quarter that ended in Oct. 2025 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Scancell Holdings was 14.00% per year. The lowest was -56.30% per year. And the median was -12.30% per year.

Scancell Holdings's current price is $0.2789. Its book value per share for the quarter that ended in Oct. 2025 was $-0.01. Hence, today's PB Ratio of Scancell Holdings is .


Scancell Holdings  (OTCPK:SCNLF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Scancell Holdings Book Value per Share Related Terms


Scancell Holdings Book Value per Share Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Book Value per Share Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.00 -0.02 -0.01 -0.01

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.02 -0.01 -0.01

SCNLF vs VRTX, REGN, ALNY: Book Value per Share Comparison

For the Biotechnology subindustry, Scancell Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's PB Ratio falls into.


SCNLF
16GF Score
Scancell Holdings PLC SCNLF
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Book Value per Share Calculation

Scancell Holdings's Book Value Per Share for the fiscal year that ended in Apr. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.04-0.00)/1,036.78
=-0.00

Scancell Holdings's Book Value Per Share for the quarter that ended in Oct. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-11.18-0.00)/1,037.78
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $-0.01 mean?
Scancell Holdings (SCNLF) has a Book Value per Share of $-0.01 as of Oct. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Scancell Holdings and its competitors.
Is Scancell Holdings' Book Value per Share too high?
Scancell Holdings' current Book Value per Share is $-0.01. Overall, Scancell Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Book Value per Share compare to VRTX and REGN?
Scancell Holdings' Book Value per Share of $-0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Book Value per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Book Value per Share of $-0.01. The current Book Value per Share is $-0.01. Scancell Holdings' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Book Value per Share is $-0.01 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
16GF Score

Get the complete analysis for SCNLF

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price